Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 7/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359907 | 1.00 | CA1 (0.42) | CA1CA2CA7ATMCTSK | |
| SCHEMBL867580 | 0.88 | CA1 (0.46) | CA1CA2CA7ATMCTSK | |
| SCHEMBL15980598 | 0.85 | CA2 (0.41) | CA1CA2CA7ATMCTSK | |
| SCHEMBL2063674 | 0.84 | CA1 (0.41) | CA1CA2CA7ATMCTSK | |
| SCHEMBL14497006 | 0.84 | CA1 (0.41) | CA1CA2CA7ATMCTSK | |
| SCHEMBL2063672 | 0.84 | CA1 (0.41) | CA1CA2CA7ATMCTSK | |
| SCHEMBL2861782 | 0.84 | CA1 (0.52) | CA1CA2CA7ATMCTSK | |
| SCHEMBL10209821 | 0.83 | CA1 (0.40) | CA1CA2CA7ATMCTSK | |
| SCHEMBL8363969 | 0.80 | CTSS (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL1809285 | 0.79 | CTSK (0.47) | CA1CA2CA7ATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307095-B2 | Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide | IRM LLC (BM) | 2007-12-11 | — | — | US | disclosed |
| US-20070123523-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-05-31 | — | — | US | disclosed |
| US-7173051-B2 | Inhibitors of cathepsin S | IRM, LLC (BM) | 2007-02-06 | — | — | US | disclosed |
| US-20050049244-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-03-03 | — | — | US | disclosed |
| WO-2004112709-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049244-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CA1 317/4885CA2 321/4885CA7 571/4885 |
| US-20070123523-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CA1 317/4885CA2 321/4885CA7 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.